Coverage, Formulary Restrictions, and Affordability of Sodium-Glucose Cotransporter 2 Inhibitors by US Insurance Plan Types
Sri Lekha Tummalapalli, Julio Lamprea Montealegre, Neil D. Warnock, Michael Green, Said A. Ibrahim, Michelle M. Estrella
Abstract
This cross-sectional study evaluates the stipulations of coverage under commercial, health insurance exchange, Veterans Affairs, Medicare, Medicaid, or other insurance for canagliflozin, dapagliflozin, empagliflozin, and ertugliflozin.
Topics & Concepts
CanagliflozinDapagliflozinFormularyEmpagliflozinMedicaidHealth insuranceBusinessActuarial scienceHealth planMedicinePharmacologyDiabetes mellitusType 2 diabetesEconomicsHealth careEconomic growthEndocrinologyDiabetes Treatment and ManagementMedication Adherence and CompliancePotassium and Related Disorders